case_images: PMC6103232_01
case_images: Primary tumour of the breast formed by uniform cells with scant, lightly eosinophilic cytoplasm, arranged in broad gyriform trabeculae. Invasive component is visible at the top, in situ component below it (H&E, 20x)
case_images: WO-22-76831-g001.jpg
case_images: PMC6103232_01_WO-22-76831-g001.jpg
case_images: f0001
case_images: Histopathological examination of the breast tumour specimen confirmed a primary neuroendocrine carcinoma of the breast (a well-differentiated neuroendocrine neoplasm - WD-NEN) with vascular invasion (Fig. 1) and the following immunophenotypes: synaptophysin+ (Fig. 2), chromogranin+, Ki67 3%, ER: 60%, PR 80%, and HER2-0.
case_images: Liver metastasis of the neuroendocrine tumor, composed by monomorphic cells arranged in trabeculae (H&E, 20x)
case_images: WO-22-76831-g003.jpg
case_images: PMC6103232_01_WO-22-76831-g003.jpg
case_images: f0003
case_images: The liver tumour specimen also revealed a neuroendocrine tumour (Fig. 3) with the following immunohistochemical characteristics: synaptophysin+ (Fig. 4), chromogranin+ (Fig. 5), GATA3+ (Fig. 6), HepPar1-, Glypican3-, Ki67 of 12%, ER 40% (Fig. 7), PR 0%, and HER2-0.
case_images: Chromogranin A expression in cells of the metastatic tumour of the liver (20x)
case_images: WO-22-76831-g005.jpg
case_images: PMC6103232_01_WO-22-76831-g005.jpg
case_images: f0005
case_images: The liver tumour specimen also revealed a neuroendocrine tumour (Fig. 3) with the following immunohistochemical characteristics: synaptophysin+ (Fig. 4), chromogranin+ (Fig. 5), GATA3+ (Fig. 6), HepPar1-, Glypican3-, Ki67 of 12%, ER 40% (Fig. 7), PR 0%, and HER2-0.
case_images: ER expression in cells of the metastatic tumour of the liver (20x)
case_images: WO-22-76831-g007.jpg
case_images: PMC6103232_01_WO-22-76831-g007.jpg
case_images: f0007
case_images: The liver tumour specimen also revealed a neuroendocrine tumour (Fig. 3) with the following immunohistochemical characteristics: synaptophysin+ (Fig. 4), chromogranin+ (Fig. 5), GATA3+ (Fig. 6), HepPar1-, Glypican3-, Ki67 of 12%, ER 40% (Fig. 7), PR 0%, and HER2-0.